These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25182571)

  • 1. A mixture model using likelihood-based and Bayesian approaches for identifying responders and non-responders in longitudinal clinical trials.
    He J; Entsuah R
    Pharm Stat; 2014; 13(5):327-36. PubMed ID: 25182571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
    Choi L; Dominici F; Zeger SL; Ouyang P
    Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian approach to two-stage phase II trial.
    Pepple PA; Choi SC
    J Biopharm Stat; 1997 May; 7(2):271-86. PubMed ID: 9136069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confidence intervals for correlated proportion differences from paired data in a two-arm randomised clinical trial.
    Pei Y; Tang ML; Wong WK; Guo J
    Stat Methods Med Res; 2012 Apr; 21(2):167-87. PubMed ID: 20442192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the success probability of a Phase III clinical trial based on Phase II data.
    Su Z
    Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A random-effects mixture model for classifying treatment response in longitudinal clinical trials.
    Xu W; Hedeker D
    J Biopharm Stat; 2001 Nov; 11(4):253-73. PubMed ID: 12018779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.
    Kim MY; Xue X
    J Clin Epidemiol; 2004 Dec; 57(12):1253-61. PubMed ID: 15617951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.
    Thall PF; Sung HG
    Stat Med; 1998 Jul; 17(14):1563-80. PubMed ID: 9699230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Molenberghs M
    Pharm Stat; 2013; 12(1):1-6. PubMed ID: 23193075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian inference for randomized clinical trials with treatment failures.
    Shaffer ML; Chinchilli VM
    Stat Med; 2004 Apr; 23(8):1215-28. PubMed ID: 15083479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data mining and statistically guided clinical review of adverse event data in clinical trials.
    Southworth H; O'Connell M
    J Biopharm Stat; 2009 Sep; 19(5):803-17. PubMed ID: 20183445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.
    Santen G; Danhof M; Della Pasqua O
    J Psychiatr Res; 2008 Oct; 42(14):1189-97. PubMed ID: 18353370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian analysis of a multivariate null intercept errors-in-variables regression model.
    Aoki R; Bolfarine H; Achcar JA; Dorival LP
    J Biopharm Stat; 2003 Nov; 13(4):767-75. PubMed ID: 14584721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.